VANCOUVER, British Columbia, Feb. 15, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to announce it has obtained positive results…

Source

Previous articlePT293 – Stanislav & Brigitte Grof – The Evolution of Breathwork and The Psychology of the Future
Next articleatai Life Sciences to Participate in Upcoming February Investor Conference